Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM

In VALOR-HCM, mavacamten resulted in an improvement in LAVI and LA strain at week 56, suggesting sustained favorable LA remodeling and improved function, except in the atrial fibrillation subgroup. Whether the advantageous LA remodeling associated with long-term treatment with mavacamten results in a favorable impact on the observed high burden of atrial tachyarrhythmias in HCM remains to be proven. (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy [VALOR-HCM]; NCT04349072).

Authors

Institutions

Publication Details

Journal
JACC. Cardiovascular imaging
Published
2024-09-02
DOI
https://doi.org/10.1016/j.jcmg.2024.08.005
Citations
32
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
12.87

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM

Pietro Bajona, Jeffrey Benjamin Geske, Zoran Popović, Kathy Lampl et al.
32 citations
JACC. Cardiovascular imaging
Cardiomyopathy and Myosin Studies
12.87
article

Mavacamten-Associated Temporal Changes in Left Atrial Function in Obstructive HCM

Pietro Bajona, Jeffrey Benjamin Geske, Zoran Popović, Kathy Lampl, John C. Stendahl, R. Bach, J. Orford, David Fermin, Paul C Cremer, Sara Saberi, Milind Y. Desai, Amy J. Sehnert, Suveeksha Naidu, ANJALI TIKU OWENS, Steven E. Nissen, Andrew Z. Wang, M. Zenker, Albree Tower‐Rader, Mark V. Sherrid, Neal K. Lakdawala, Matthew Thomas Wheeler, Srihari S. Naidu, Ahmad Masri, Florian Rader, Yuichiro Okushi, Andrew Wang, Kathy Wolski, Neal K. Lakdawala
article en
32 citations

Abstract

In VALOR-HCM, mavacamten resulted in an improvement in LAVI and LA strain at week 56, suggesting sustained favorable LA remodeling and improved function, except in the atrial fibrillation subgroup. Whether the advantageous LA remodeling associated with long-term treatment with mavacamten results in a favorable impact on the observed high burden of atrial tachyarrhythmias in HCM remains to be proven. (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy Who Are Eligible for Septal Reduction Therapy [VALOR-HCM]; NCT04349072).

JACC. Cardiovascular imagingVol. 18(3)
Cleveland Clinic (US), Westchester Medical Center (US), Mayo Clinic (US), Duke University (US), University of Michigan (US), Bristol-Myers Squibb (United States) (US), Trinity Health Grand Rapids (US), Center for Clinical Research (United States) (US), Corewell Health, Mass General Brigham (US), New York University (US), University of Pennsylvania (US)
Bristol-Myers Squibb, Celgene
Openalex Percentile: Top 1%
Cardiomyopathy and Myosin Studies
12.87
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.